| Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B DAE Cross, DR Alessi, P Cohen, M Andjelkovich, BA Hemmings Nature 378 (6559), 785-789, 1995 | 6745 | 1995 |
| AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer DAE Cross, SE Ashton, S Ghiorghiu, C Eberlein, CA Nebhan, PJ Spitzler, ... Cancer discovery 4 (9), 1046-1061, 2014 | 2286 | 2014 |
| Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription MP Coghlan, AA Culbert, DAE Cross, SL Corcoran, JW Yates, NJ Pearce, ... Chemistry & biology 7 (10), 793-803, 2000 | 1124 | 2000 |
| Kinase drug discovery 20 years after imatinib: progress and future directions P Cohen, D Cross, PA Jänne Nature reviews drug discovery 20 (7), 551-569, 2021 | 852 | 2021 |
| Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity P Ballard, JWT Yates, Z Yang, DW Kim, JCH Yang, M Cantarini, K Pickup, ... Clinical Cancer Research 22 (20), 5130-5140, 2016 | 710 | 2016 |
| The inhibition of glycogen synthase kinase-3 by insulin or insulin-like growth factor 1 in the rat skeletal muscle cell line L6 is blocked by wortmannin, but not by rapamycin … DAE Cross, DR Alessi, JR Vandenheede, HE McDowell, HS Hundal, ... Biochemical Journal 303 (1), 21-26, 1994 | 639 | 1994 |
| Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor MRV Finlay, M Anderton, S Ashton, P Ballard, PA Bethel, MR Box, ... Journal of medicinal chemistry 57 (20), 8249-8267, 2014 | 599 | 2014 |
| Selective small‐molecule inhibitors of glycogen synthase kinase‐3 activity protect primary neurones from death DAE Cross, AA Culbert, KA Chalmers, L Facci, SD Skaper, AD Reith Journal of neurochemistry 77 (1), 94-102, 2001 | 480 | 2001 |
| Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background BR Davies, H Greenwood, P Dudley, C Crafter, DH Yu, J Zhang, J Li, ... Molecular cancer therapeutics 11 (4), 873-887, 2012 | 479 | 2012 |
| PDK1, one of the missing links in insulin signal transduction? P Cohen, DR Alessi, DAE Cross FEBS letters 410 (1), 3-10, 1997 | 361 | 1997 |
| Acquired resistance to the mutant-selective EGFR inhibitor AZD9291 is associated with increased dependence on RAS signaling in preclinical models CA Eberlein, D Stetson, AA Markovets, KJ Al-Kadhimi, Z Lai, PR Fisher, ... Cancer research 75 (12), 2489-2500, 2015 | 327 | 2015 |
| Characterization of VPS34-IN1, a selective inhibitor of Vps34, reveals that the phosphatidylinositol 3-phosphate-binding SGK3 protein kinase is a downstream target of class III … R Bago, N Malik, MJ Munson, AR Prescott, P Davies, E Sommer, N Shpiro, ... Biochemical Journal 463 (3), 413-427, 2014 | 317 | 2014 |
| ATR is a caffeine-sensitive, DNA-activated protein kinase with a substrate specificity distinct from DNA-PK CA Hall-Jackson, DAE Cross, N Morrice, C Smythe Oncogene 18 (48), 6707-6713, 1999 | 314 | 1999 |
| Structure-and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR) RA Ward, MJ Anderton, S Ashton, PA Bethel, M Box, S Butterworth, ... Journal of medicinal chemistry 56 (17), 7025-7048, 2013 | 288 | 2013 |
| Insulin activates protein kinase B, inhibits glycogen synthase kinase-3 and activates glycogen synthase by rapamycin-insensitive pathways in skeletal muscle and adipose tissue DAE Cross, PW Watt, M Shaw, J Van Der Kaay, CP Downes, JC Holder, ... FEBS letters 406 (1-2), 211-215, 1997 | 279 | 1997 |
| Current status and future perspectives on neoadjuvant therapy in lung cancer GM Blumenthal, PA Bunn Jr, JE Chaft, CE McCoach, EA Perez, ... Journal of Thoracic Oncology 13 (12), 1818-1831, 2018 | 208 | 2018 |
| Elevated SGK1 predicts resistance of breast cancer cells to Akt inhibitors EM Sommer, H Dry, D Cross, S Guichard, BR Davies, DR Alessi Biochemical Journal 452 (3), 499-508, 2013 | 191 | 2013 |
| Preclinical comparison of the blood–brain barrier permeability of osimertinib with other EGFR TKIs N Colclough, K Chen, P Johnström, N Strittmatter, Y Yan, GL Wrigley, ... Clinical Cancer Research 27 (1), 189-201, 2021 | 166 | 2021 |
| Targeting HER2 Aberrations in Non–Small Cell Lung Cancer with Osimertinib S Liu, S Li, J Hai, X Wang, T Chen, MM Quinn, P Gao, Y Zhang, H Ji, ... Clinical Cancer Research 24 (11), 2594-2604, 2018 | 141 | 2018 |
| SFK/FAK signaling attenuates osimertinib efficacy in both drug-sensitive and drug-resistant models of EGFR-mutant lung cancer E Ichihara, D Westover, CB Meador, Y Yan, JA Bauer, P Lu, F Ye, A Kulick, ... Cancer research 77 (11), 2990-3000, 2017 | 133 | 2017 |
